Chairman of the Board. Adjunct Professor of Cancer Biology, an expert of rare cancer research.
The Chairman of the Board, Dr. Harri Sihto (born 1976) is a founding member of the Company. He is a biochemist, who received his Ph.D. degree in 2012 and was awarded with title of Adjunct Professor of Cancer Biology in 2015 at the University of Helsinki, Finland. Dr. Sihto’s research group investigates novel therapy targets in sarcomas and other rare cancers to discover new therapeutic options for the patients. Dr. Sihto is an author in dozens of scientific publications, which are cited thousands of times. Dr. Sihto is responsible for the management of the company at present.